The Food & Drug Administration announced today it will convene a public meeting in October to review the psychiatric and behavioral side effects of Chantix. In 2009 the FDA required a “black box” label warning of hostility, agitation depression and suicidal thoughts after dozens of suicides and hundreds of reports of suicidal behavior were connected to the anti-smoking drug.
FDA Reviews Psychiatric Side Effects of Chantix (Boston.com)
FDA Reviews Psychiatric Side Effects of Chantix (ABC News)
FDA Reviewing Psychiatric Side Effects of Pfizer’s Chantix (Wall Street Journal)